MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The ...

Riyadh, November 19, 2023, SPA -- An agreement was signed today at the Ministry of Industry and Mineral Resources between Dammam Pharma, 85% owned by Spimaco, and MSD to manufacture type 2 diabetes ...

Only show cars that can be delivered to me. Please enter your postal code in order to show cars that can be delivered to you.